Financial Health Snapshot
What do the latest financial-health metrics show for IDEXX Laboratories?
Strong. The strongest factor is cash conversion, while the main concern is visit-demand pressure that could soften operating momentum.
The latest verified fiscal period is FY2025, with the latest quarter for margin detail from Q4 2025. This view combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so it shows how well IDEXX Laboratories can fund growth and return cash while staying resilient.
Total 2025 Share Repurchases were $122B, up 4539% from 2024, which shows active capital returns; for deeper context, see Mission Statement, Vision, & Core Values (2026) of IDEXX Laboratories, Inc. (IDXX). Revenue growth deserves deeper analysis first.
Revenue Quality
Are IDEXX Laboratories revenue and earnings high quality?
Strong. Revenue growth is backed by sharp gains in operating income, net income, and diluted EPS, which points to real earnings quality. The clearest support is the recurring diagnostics model, though concentration in Companion Animal Group and softer U.S. visit trends still matter.
IDEXX Laboratories looks stronger on quality than on sales alone because recurring diagnostics, consumables, and reference lab services support repeat revenue. Investors compare revenue durability with operating income, net income, and EPS across compatible periods to see whether growth turns into profit, not just top-line expansion. See IDEXX Laboratories, Inc. (IDXX): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $114B, 461% growth, quarter ended 2026-03-31 | $430B, full year 2025 | Organic, supported by recurring diagnostics, premium instrument placements, consumables, reference lab services, cloud-native software, and 4% net price realization in 2025 | Looks repeatable if recurring demand holds, but the current comparison period is not directly like-for-like |
| Operating Income | $36259M, 1489% growth, quarter ended 2026-03-31 | Previous comparable value not supplied | Grew faster than revenue | Strong operating leverage confirms high-quality growth |
| Net Income | $27845M, 1219% growth, quarter ended 2026-03-31 | Previous comparable value not supplied | Verified operating result, with no other effects supplied | Final earnings also confirm the operating result |
| Diluted EPS | $345, 1201% growth, quarter ended 2026-03-31 | Previous comparable diluted EPS not supplied | Share-count effect not supplied | Shareholders appear to have captured strong per-share growth |
How durable is IDEXX Laboratories revenue?
Fairly durable. The strongest signal is recurring diagnostics tied to the Companion Animal Group model, but the biggest visibility limit is concentration, since Companion Animal Group contributed 92% of total 2024 revenue.
- Demand Quality: Repeat purchases are supported by diagnostics, consumables, and lab services, so visibility is better than a one-time product sale.
- Pricing and Volume: Growth included 4% net price realization in 2025, but the price and volume split beyond that is unavailable.
- Diversification: Concentration is high because Companion Animal Group contributed 92% of total 2024 revenue.
That makes cash conversion and margin resilience the next checks.
Profitability and Cash
Does IDEXX Laboratories turn profit into cash?
Yes, IDEXX Laboratories shows strong profit-to-cash conversion over the full year, with $1.06B FY2025 net income and $1.1B FY2025 free cash flow, or about 100% conversion. Near term, cash flow was volatile in the quarter ended 2026-03-31, even as operating margin improved to 289% year over year.
Gross, operating, and net margins show how much profit IDEXX Laboratories keeps at each stage, while net income is the accounting result. Cash quality is different: operating cash flow shows cash from daily operations, and free cash flow is what remains after capital spending. That makes the link between earnings and cash important for valuation and strategy. For broader context on direction and culture, see Mission Statement, Vision, & Core Values (2026) of IDEXX Laboratories, Inc. (IDXX).
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable from supplied data | Unavailable from supplied data | Gross profit was $72274M, but no verified gross margin was supplied. | Suggests product economics may be strong, but the margin trend cannot be verified here. |
| Operating Margin | 289% quarter ended 2026-03-31 | 274% quarter ended 2025-03-31 | Year-over-year increase of 150 basis point; pricing, mix, and operating cost discipline were the only verified themes provided. | Signals better operating efficiency and scale leverage. |
| Net Margin | Unavailable from supplied data | Unavailable from supplied data | Net income was $27845M, but no verified net margin was supplied. | Final profitability is positive, but the margin trend cannot be confirmed from the provided figures. |
| Operating Cash Flow | Unavailable from supplied data; quarter ended 2026-03-31 OCF growth was -2437% | Unavailable from supplied data | Direction diverged from earnings, but the supplied data does not isolate the working-capital effect. | Shows earnings did not translate smoothly into quarterly cash. |
| Free Cash Flow | $11B FY2025 | Unavailable from supplied data | Free cash flow was reported, but capex was not supplied. | Leaves meaningful capacity for reinvestment, debt service, or shareholder returns. |
What most affects IDEXX Laboratories cash conversion?
The strongest verified driver is operating performance: IDEXX Laboratories held a higher operating margin while FY2025 free cash flow reached $11B. The quarter’s -2437% operating cash flow growth shows timing can still distort cash conversion.
- Main Driver: Operating margin expansion appears structural, tied to pricing, mix, and cost control.
- Evidence Gap: The supplied data does not isolate working-capital moves, capex, or one-time items.
- Metric to Monitor: Watch operating cash flow and free cash flow in the next quarter.
Balanced Liquidity
How strong is IDEXX Laboratories, Inc. balance sheet for obligations and investment needs?
Mixed. IDEXX Laboratories, Inc. has a solid equity base and strong cash generation, but the main concern is leverage and liquidity coverage because cash is modest versus $108B of total debt, $130B of current liabilities, and $714M of quarterly interest expense.
Cash alone does not tell the full story. To judge IDEXX Laboratories, Inc., you have to look at working capital, asset quality, debt service, solvency, liquidity, and refinancing together. That is the right lens for academic analysis, and it also fits a broader investor review such as Exploring IDEXX Laboratories, Inc. (IDXX) Investor Profile: Who's Buying and Why?.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents were $20053M; Total Current Assets were $145B; Total Current Liabilities were $130B. | Mixed | Near-term obligations look manageable, but cash is not large enough to fully offset the current liability load without continued operating cash flow. |
| Total and Net Debt | Total Debt was $108B; Net Debt was $87807M; Short Term Debt was $68000M; Long Term Debt was $29985M; Capital Lease Obligations Non Current were $9875M. | Mixed | Leverage is meaningful, so flexibility is more limited than a low-debt balance sheet, even with positive cash generation. |
| Debt Service and Refinancing | Interest Expense was $714M for the quarter ended 2026-03-31; no maturity schedule, rate, or covenant detail was supplied. | Mixed | Interest can be serviced from operations if cash flow stays strong, but refinancing pressure cannot be measured precisely from the supplied data. |
| Asset Quality | Goodwill was $41210M and Intangible Assets were $10475M out of Total Assets of $339B. | Mixed | A large acquisition-related asset base can support growth, but it also raises impairment and valuation risk if performance weakens. |
| Liabilities and Equity | Total Liabilities were $183B; Total Stockholders Equity was $156B. | Mixed | The equity cushion is sizeable, but liabilities are also substantial, so the capital base can absorb shocks only if earnings remain steady. |
Which balance-sheet risk matters most for IDEXX Laboratories, Inc.?
Debt load is the biggest risk. The clearest pressure point is $108B of total debt against $20053M of cash, with $714M in quarterly interest expense making liquidity discipline important.
- Current Exposure: Total Current Liabilities were $130B, while Cash And Cash Equivalents were $20053M.
- Protection: Total Stockholders Equity was $156B, giving IDEXX Laboratories, Inc. a meaningful capital buffer.
- Warning Signal: Watch whether debt stays high relative to cash and whether interest expense keeps rising.
Capital Efficiency
Is IDEXX Laboratories using capital efficiently?
Strong. IDEXX Laboratories appears to fund reinvestment internally, with FY2025 Free Cash Flow of $11B and 100% net income conversion. That supports ongoing growth, buybacks, and flexibility. For strategy context, see Mission Statement, Vision, & Core Values (2026) of IDEXX Laboratories, Inc. (IDXX).
Return quality should still be judged with leverage, asset intensity, capital expenditure, working capital, and outside funding needs. High cash conversion can look strong even when growth requires heavy reinvestment, so the key question is whether operating cash covers expansion, repurchases, and any debt service without pressure on balance sheet flexibility.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Operating cash conversion and reinvestment discipline support capital efficiency, but no numeric ROIC can be verified here. | Invested capital appears to be creating operating value if cash flow stays strong and growth spending remains productive. |
| ROE and ROA | Unavailable in the supplied data. | ROE may be helped by buybacks and any leverage; ROA depends on how efficiently assets support diagnostics, software, and AI growth. | Shareholder returns look healthier when they come from earnings and cash generation, not just financial leverage. |
| Maintenance and Growth Investment | R&D Expenses of $6579M for 2026-03-31, plus inVue Dx placements of nearly 6,400 units for full year 2025 and expansion in diagnostics, software, and AI. | The evidence points to meaningful growth investment, not just maintenance spending. | Capital is being used to expand the product base and support future revenue, which can lift long-term returns if adoption holds. |
| Internal Funding Capacity | FY2025 Free Cash Flow of $11B, 100% net income conversion, Total 2025 Share Repurchases were $122B, and Share Repurchases were $37139M for the first quarter of 2026. | Investment appears internally funded, with buybacks also supported by cash generation, while the Board authorized an additional 5M common shares on December 09, 2024. | Internal funding reduces dilution risk and supports flexibility, but continued buybacks still depend on durable cash flow and manageable debt. |
Are IDEXX Laboratories' returns on capital sustainable?
Mostly yes. The strongest durability signal is 100% net income conversion plus strong free cash flow; returns weaken if growth spending, buybacks, or debt demands start to outpace operating cash generation.
- Operating Source: Cash conversion, supported by profit growth and product expansion in diagnostics, software, and AI.
- Funding Requirement: Growth R&D, inVue Dx placements, and share repurchases.
- Durability Test: Watch whether free cash flow stays ahead of reinvestment needs and debt pressure.
Financial Resilience
What could weaken IDEXX Laboratories financial resilience?
Resilience is Mixed. The main buffer is recurring diagnostics demand, but the most important verified warning sign is weaker clinical visit volume, since U.S. same-store clinical visits declined 17% in Q4 2025 and 19% for full year 2025, with another 2% decline forecast for 2026.
IDEXX Laboratories can still fund operations and essential investment because its diagnostics model is recurring and it posted 4% net price realization in 2025, plus a 60 basis point foreign currency benefit to 2026 revenue growth projections. The risk is that softer clinic traffic, supplier concentration, or weaker cash conversion could reduce operating leverage and make future investment less flexible.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower same-store visits can slow revenue growth, hurt operating leverage, and squeeze earnings, cash flow, and debt capacity if fixed costs stay high. | Recurring diagnostics revenue and 4% net price realization in 2025 help support pricing and repeat demand. | Further decline in clinical visits, weaker revenue growth, or margin compression would confirm deterioration. |
| Working-Capital or Investment Pressure | More receivables, inventory, or expansion spending could absorb cash and reduce flexibility if operating cash generation weakens. | Internal funding capacity is supported by recurring demand and 2025 Free Cash Flow of $11B. | Watch for weaker operating cash flow, slower cash conversion, or rising investment needs relative to sales. |
| Interest or Refinancing Pressure | Even if debt is manageable, weaker free cash flow would reduce interest coverage and financing flexibility if borrowing needs rise. | Cash generation from a subscription-like diagnostics base supports debt service better than a volatile one-time sales model. | Any rise in debt, refinancing stress, or a drop in free cash flow would show tighter liquidity. |
Which financial warning signs should investors monitor at IDEXX Laboratories?
The strongest signals are clinical visit trends, operating cash flow, and supplier disruption. The visit decline is confirmed deterioration; supplier reliance and cash-flow volatility are future risks that could become problems if they start to hit revenue or liquidity.
Clinical visit decline
U.S. same-store clinical visits fell 17% in Q4 2025 and 19% for full year 2025, with another 2% decline expected in 2026. That is the clearest demand risk, and the next metric is visit volume versus price growth.
Supplier concentration risk
IDEXX Laboratories identified supply chain risk from reliance on sole and single-source suppliers for certain diagnostic imaging components. The exposure is disruption, and the key monitor is component availability, lead times, and any inventory or shipment delays.
Cash-flow volatility
Quarter ended 2026-03-31 Operating Cash Flow Growth was -2437% and Free Cash Flow Growth was -2738%, so cash conversion needs close watch. The mitigating factor is recurring diagnostics demand, and the next metric is operating cash flow versus debt needs.
Financial Health Scorecard
What does IDEXX Laboratories financial health mean for investors?
Overall rating: Strong. The biggest strength is cash conversion, while the main weakness is visit-driven demand pressure. The most important condition for the investment case is whether recurring diagnostics revenue keeps turning into free cash flow despite slower clinical traffic.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | FY2025 revenue growth of 10% and quarter ended 2026-03-31 Net Income Growth of 1219% show durable demand and strong per-share earnings leverage. |
| Profitability and Cash | Strong | Q4 2025 Operating Margin of 289% and FY2025 Free Cash Flow of $1.1B point to excellent cash generation and high earnings conversion. |
| Balance Sheet and Liquidity | Mixed | Cash And Cash Equivalents were $20053M versus Total Debt of $1.08B and Net Debt of $87807M at 2026-03-31, so liquidity is solid but leverage needs monitoring. |
| Capital Efficiency | Strong | Internal cash generation and buybacks support returns, but repurchase discipline matters because capital efficiency depends on funding them without weakening flexibility. |
| Financial Resilience | Mixed | Recurring diagnostics revenue helps offset visit declines, but supplier reliance and softer clinical traffic remain pressure points if demand weakens further. |
- What Supports the Thesis: Strong revenue growth, very high cash conversion, and recurring diagnostics demand create a durable earnings and liquidity profile.
- What Challenges the Thesis: Clinical visit declines can slow growth and test how much of revenue momentum is structural versus cyclical.
- What to Monitor: US same-store clinical visits, free cash flow conversion, Net Debt.
This scorecard is most useful for forecast scenarios and valuation work, and the company background is here: IDEXX Laboratories, Inc. (IDXX): History, Ownership, Mission, How It Works & Makes Money.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How strong was IDEXX's free cash flow conversion?
FY2025 Free Cash Flow was $11B, representing 100% net income conversion That is a strong financial-health signal because reported profit translated into cash available for reinvestment, repurchases, debt management, or liquidity support
Does IDEXX need debt to fund repurchases?
The supplied data do not prove that IDEXX needs debt to fund repurchases FY2025 Free Cash Flow was $11B, while Total 2025 Share Repurchases were $122B Investors should compare future buybacks with free cash flow, cash balances, and Net Debt
What does 92% CAG revenue concentration mean?
CAG contributing 92% of total 2024 revenue means IDEXX depends heavily on companion-animal diagnostics and related services That supports recurring revenue quality, but it also makes veterinary clinic demand, instrument placements, consumable use, and clinical visit trends central to financial health
Why does the 2026 visit decline matter?
The company forecast a further 2% visit decline for 2026 after US same-store clinical visits declined 17% in Q4 2025 and 19% for the full year 2025 Lower visits can pressure testing volume and growth visibility
What does IDEXX liquidity risk look like?
At 2026-03-31, IDEXX had Cash And Cash Equivalents of $20053M, Total Current Assets of $145B, Total Current Liabilities of $130B, Total Debt of $108B, and Net Debt of $87807M Liquidity looks manageable but worth monitoring